The historic rise of Viagra has consistently remained a example of pharmaceutical success, but its legacy within the broader sector now triggers questions about long-term yields . Copycat versions are diminishing market share, prompting concerns that investing in companies closely tied to Viagra's former influence could be a problematic decision ,